StockWatch
·

Max Healthcare Institute Ltd

BSE: 543220

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
891.08
+1.8%+13.7%
Expenditure
664.93
+2.4%+17.0%
Net Profit
168.33
+0.4%+4.9%
OPM %
27.26%
+3.95pp-1.75pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00249.50499.00748.51998.01Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Revenue Soars 20% but Profit Halts—a Margin Collapse Under Regulatory & Brownfield Drag

margin compression · brownfield drag · oncology headwind

Result verdictFollow-upQ2 FY2709 Nov 20266 minPharma & Healthcare

Revenue growth masks 15.6% PAT decline; margin pressure persists

margin compression · brownfield ramp-up · oncology headwind

TranscriptDeep diveQ2 FY2709 Nov 20266 minPharma & Healthcare

Max Healthcare Q2 FY27: revenue +20% YoY, consolidated PAT -16% on tax base (adj. flat)

hospitals · margin expansion · capacity expansion

ResultsQ2 FY2730 Oct 20263 minPharma & Healthcare
Latest
Quarterly Result30 Oct, 2:47 pm

Max Healthcare Q2 FY27: revenue +20% YoY, consolidated PAT -16% on tax base (adj. flat)

Max Healthcare's consolidated revenue rose 20.3% YoY to ₹2,569.21 Cr (+8.6% QoQ) in Q2 FY27, while consolidated PAT (profit for the period) came in at ₹414.45 Cr, down 15.6% YoY but up 28.3% QoQ. The YoY profit decline is a base-effect artefact rather than an operating miss: Q2 FY26 tax expense included a one-off ₹79.39 Cr current-tax reversal credit booked on the Crosslay Remedies (formerly Jaypee Healthcare) merger, which lifted that quarter's reported PAT to ₹491.30 Cr. Stripping that one-off out, adjusted YoY PAT growth is roughly flat (~+0.6%), a materially different read from the -15.6% headline. Operating margin actually expanded both YoY and QoQ — OPM rose to 27.69% from 26.93% a year ago and 25.29% last quarter — so the underlying business got more profitable at the EBITDA line even as reported net profit margin fell to 15.88% from 22.66% YoY (13.42% in Q1 FY27), the gap being almost entirely the tax-line swing described above, not cost pressure. This runs counter to the prior concall's caution that near-term EBITDA would stay muted as new beds at Max Smart, Nanavati and Sector-56 Gurgaon absorb fixed costs before ramping — margins held up better than that framing implied, even as the company confirmed network-wide capacity utilisation stayed high at >75% across 6,100+ beds. Part of the topline growth is inorganic: Kalinga Hospital (acquired, 58.28% then raised to 66.34% via rights issue, consolidated from May 18, 2026) and Yerawada Properties (YPPL, from June 30, 2026) are in the Q2 FY27 base but were absent or partial in the year-ago quarter, so like-for-like organic growth is lower than the 20.3% headline — the filing does not break out the split. Alongside results, the Board approved fresh capex of ~₹93 Cr for Max Super Speciality Hospital Noida (+85 beds) and ~₹97 Cr for Vaishali (+60 beds), and revised the cost of the 525-bed Sector-56 Gurgaon greenfield project upward to ~₹1,143 Cr with completion pushed out to April 2027 (from the original schedule), citing façade, atrium and interior fit-out changes. No separate management press release was available to cross-check tone against the numbers, and no broker consensus for this specific quarter was found in search (results were announced same-day), so vs-street is left unresolved. Standalone (holding-company-only, ex most hospital subsidiaries) PAT was ₹168.33 Cr on revenue of ₹841.97 Cr, +14.3% YoY — consolidated remains the primary read since the bulk of hospital operations sit in subsidiaries and silos. Going into Q3, the key markers are whether CGHS recoveries stay on track for management's ₹140 Cr FY27 target (not disclosed this quarter), how fast the new Noida/Vaishali/Gurgaon beds ramp given the extended Gurgaon timeline, and the outcome of the Kalinga Hospital NCLT hearing (adjourned again, next date pending), which sits with a subsidiary and is not yet material to Group financials per the auditor's note.

30 Oct 2026, 02:47 pm

Corporate Events

Board MeetingMAXHEALTH
2026
30Oct

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingMAXHEALTH
2026
3Sep

Board Meeting

The Renewable Energy and Subsidiary Investment Committee (RE…

BSE Filing ↗
Board MeetingMAXHEALTH
2026
13Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingMAXHEALTH
2026
30Jul

Board Meeting

The Annual General Meeting will be held to adopt audited fin…

BSE Filing ↗
DividendMAXHEALTH
2026
3Jul

₹2 / share

BSE Filing ↗
Board MeetingMAXHEALTH
2024
1Aug

Board Meeting

consider and approve unaudited standalone and consolidated f…

BSE Filing ↗
Board MeetingMAXHEALTH
2024
22May

Board Meeting

consider and approve standalone and consolidated financial r…

BSE Filing ↗
Board MeetingMAXHEALTH
2024
31Jan

Board Meeting

Consider and approve unaudited standalone and consolidated f…

BSE Filing ↗
Board MeetingMAXHEALTH
2023
6Nov

Board Meeting

Consider and approve unaudited standalone and consolidated f…

BSE Filing ↗